Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Censoring Survival Data

Censoring Survival Data

Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different reasons...

Holter Monitor: 24-Hour Monitoring

Holter Monitor: 24-Hour Monitoring

Holter monitoring is a continuous electrocardiography (ECG) recording that tracks the heart's electrical activity over an extended period, generally 24 to 48 hours. This noninvasive diagnostic tool detects irregular heart rhythms that may not be captured during a standard ECG performed in a clinical setting.DeviceThe Holter monitor is a portable, small device connected to several electrodes on the patient's chest. These electrodes detect the heart's electrical signals and transmit them to the...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?

The British journal of dermatology·2020

Same author

Disease course patterns in systemic lupus erythematosus.

Lupus·2018

Same author

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Arthritis research & therapy·2018

Same author

Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines.

Arthritis research & therapy·2018

Same author

Severe brady-arrhythmias in systemic lupus erythematosus: prevalence, etiology and associated factors.

Lupus·2018

Same author

Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies.

Lupus·2018

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

SLEDAI-2K for a 30-day window.

Z Touma¹, M B Urowitz, D D Gladman

¹University of Toronto Lupus Clinic, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, M5T 2S8, Canada.

|November 14, 2009

Summary

This summary is machine-generated.

The 30-day Systemic Lupus Erythematosus Disease Activity Index 2K (SLEDAI-2K) score is equivalent to the standard 10-day score. This finding supports using the 30-day SLEDAI-2K for assessing lupus disease activity.

More Related Videos

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Published on: September 12, 2017

Related Experiment Videos

Last Updated: Jun 18, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Measuring In Vivo Changes in Extracellular Neurotransmitters During Naturally Rewarding Behaviors in Female Syrian Hamsters

Published on: September 12, 2017

Area of Science:

Rheumatology
Clinical Immunology
Systemic Lupus Erythematosus Research

Background:

The Systemic Lupus Erythematosus Disease Activity Index 2K (SLEDAI-2K) is a crucial tool for assessing disease activity in lupus patients.
Current guidelines recommend a 10-day period for calculating SLEDAI-2K, which may not fully capture disease fluctuations.

Purpose of the Study:

To evaluate the equivalence of the SLEDAI-2K calculated over a 30-day period versus the standard 10-day period.
To determine if a 30-day assessment window is a reliable alternative for measuring lupus disease activity.

Main Methods:

A cohort of 149 consecutive lupus patients was enrolled at the University of Toronto Lupus Clinic.
The SLEDAI-2K score was calculated twice for each patient: once using a 10-day window and again using a 30-day window prior to their visit.

Main Results:

High agreement was observed between the 10-day and 30-day SLEDAI-2K scores in 148 out of 149 patients.
This agreement was consistent across patients with inactive disease (SLEDAI-2K score of 0) and those with varying levels of disease activity (scores 1-31).

Conclusions:

The 30-day SLEDAI-2K calculation demonstrates strong equivalence to the 10-day period.
The findings suggest that the 30-day SLEDAI-2K can be reliably used to assess disease activity over the preceding month in lupus patients.